MedPath

Folic acid

Generic Name
Folic acid
Brand Names
Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, EnBrace HR, EnLyte, Ferralet 90, Folbic, Foltabs, Hematogen, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Magnebind 400 Rx, Mvc-fluoride, Mvi Pediatric, Natafort, Nicomide, Pregvit, Tandem Plus, Vitafol-one
Drug Type
Small Molecule
Chemical Formula
C19H19N7O6
CAS Number
59-30-3
Unique Ingredient Identifier
935E97BOY8

Overview

Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As humans are unable to synthesize folic acid endogenously, diet and supplementation is necessary to prevent deficiencies. For example, folic acid is present in green vegetables, beans, avocado, and some fruits. In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted by anti-metabolite therapies such as Methotrexate as they function as DHFR inhibitors to prevent DNA synthesis in rapidly dividing cells, and therefore prevent the formation of DHF and THF. When used in high doses such as for cancer therapy, or in low doses such as for Rheumatoid Arthritis or psoriasis, Methotrexate impedes the body's ability to create folic acid. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects. As a result, supplementation with 1-5mg of folic acid is recommended to prevent deficiency and a number of side effects associated with MTX therapy including mouth ulcers and gastrointestinal irritation. Leucovorin (also known as folinic acid) supplementation is typically used for high-dose MTX regimens for the treatment of cancer. Levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF) and are able to bypass DHFR reduction to act as a cellular replacement for the co-factor THF. There are also several antiepileptic drugs (AEDs) that are associated with reduced serum and red blood cell folate, including Carbamazepine (CBZ), Phenytoin (PHT), or barbiturates. Folic acid is therefore often provided as supplementation to individuals using these medications, particularly to women of child-bearing age. Inadequate folate levels can result in a number of health concerns including cardiovascular disease, megaloblastic anemias, cognitive deficiencies, and neural tube defects (NTDs). Folic acid is typically supplemented during pregnancy to prevent the development of NTDs and in individuals with alcoholism to prevent the development of neurological disorders, for example.

Indication

Folic acid is indicated for the treatment of folic acid deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood.

Associated Conditions

  • Anaemia folate deficiency
  • Folate deficiency
  • Iron Deficiency (ID)
  • Iron Deficiency Anemia (IDA)
  • Latent Iron Deficiency
  • Neural Tube Defects (NTDs)
  • Vitamin Deficiency
  • Methotrexate toxicity

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/10/15
Phase 2
Recruiting
2024/09/24
Phase 4
Recruiting
Yongquan Shi
2024/05/08
Phase 3
Not yet recruiting
2023/08/29
Phase 4
Not yet recruiting
2023/07/25
Phase 2
Recruiting
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023/07/13
Not Applicable
Completed
Near East University, Turkey
2023/06/27
Phase 1
Recruiting
2023/05/17
Phase 2
Not yet recruiting
Wuhan Union Hospital, China
2023/03/20
Phase 2
Not yet recruiting
Liaoning Tumor Hospital & Institute
2023/02/09
Phase 2
Not yet recruiting
Liaoning Tumor Hospital & Institute

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
AvPAK
50268-677
ORAL
1 mg in 1 1
4/12/2022
REMEDYREPACK INC.
70518-4338
ORAL
1 mg in 1 1
5/20/2025
CarWin Pharmaceutical Associates, LLC
15370-105
ORAL
100 ug in 1 1
1/10/2024
MISSION PHARMACAL COMPANY
0178-0812
ORAL
1 mg in 1 1
5/3/2010
Mission Pharmacal Company
0178-0813
ORAL
1.4 mg in 1 1
1/5/2024
Method Pharmaceuticals, LLC
58657-164
ORAL
300 ug in 1 1
12/9/2023
Avion Pharmaceuticals, LLC
75854-344
ORAL
250 ug in 1 1
4/8/2025
Exeltis USA, Inc.
0642-7473
ORAL
680 mg in 1 1
2/14/2023
Marnel Pharmaceuticals, Inc.
0682-3001
ORAL
1 mg in 1 1
5/2/2014
Centurion Labs, LLC
23359-105
ORAL
1 mg in 1 1
1/22/2024

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
EUROFER CHEW TABLETS
SIN12633P
TABLET
350 mcg
12/23/2004
IBERET-FOLIC-500 TABLET
SIN05447P
TABLET, FILM COATED
800 mcg
2/19/1991
FBC FILMTAB
SIN05814P
TABLET, FILM COATED
100 mcg
5/3/1991
TAMIPOOL FOR INJECTION
SIN11849P
INJECTION, POWDER, FOR SOLUTION
400 mcg/vial
3/15/2002
CERNEVIT FOR INJECTION
SIN11975P
INJECTION, POWDER, FOR SOLUTION
0.414 mg/vial
6/5/2002
SOLUVIT N FOR INFUSION
SIN05209P
INJECTION, POWDER, FOR SOLUTION
0.4 mg/vial
11/14/1990

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
CERNEVIT FOR INJ
N/A
N/A
N/A
4/18/2008

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
FEFOL Iron and Folic Acid Delayed Release Capsules blister pack
12987
Medicine
A
8/14/1991
Energy Multi
453128
Medicine
A
6/21/2024
Cellula-T oral powder jar
43995
Hong Sp & Hs
Medicine
A
4/13/1993
Caruso's St John's Wort
286553
Medicine
A
3/9/2017
BLACKMORES SUPERKIDS MULTI CHEWABLES
289492
Medicine
A
5/30/2017
Super B Complex tablets
126510
Medicine
A
3/28/2006
BLACKMORES B+C TABLETS
215811
Medicine
A
10/9/2013
MaxN-Fuze Multivitamins
288444
Max Health & Living Australia Pty Ltd
Medicine
A
5/1/2017
Blackmores Bio Iron (NZ)
143952
Medicine
A
8/29/2007
Wealthy Health Bio-Maxi B Excellent Stress Relief Formula with Herbs
139048
Medicine
A
5/21/2007

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
CENTURY PLUS
vita health products inc
N/A
Tablet - Oral
.4 MG / TAB
2/5/1998
C.R.D.-FORCE
prairie naturals
02244717
Capsule - Oral
1 MG / 2 CAP
9/19/2001
BSELTZER
abundance naturally ltd
02244569
Powder (Effervescent) - Oral
0.4 MG / 10.6 G
11/11/2001
STRESS B COMPLEX WITH C AND E TAB
02008947
Tablet - Oral
.4 MG / TAB
12/31/1993
STRESS B WITH 1000 MG VITAMIN C
holista health (canada) inc.
02246252
Tablet - Oral
1 MG
11/13/2002
STRESS B PLUS VITAMINS & MINERALS
great earth companies, inc.
02231749
Tablet (Extended-Release) - Oral
0.8 MG / TAB
9/25/1998
MULTIPLE VITAMINS PLUS IRON FOR WOMEN
pharmetics (2011) inc
02239678
Tablet - Oral
0.4 MG / TAB
8/16/1999
MULTIVITAMINS AND MINERALS - FORTE
vita health products inc
02239947
Tablet - Oral
0.6 MG / TAB
2/1/2000
STRESS B CAPSULES WITH VITAMIN C
rheingold food international ltd.
00694509
Capsule - Oral
.2 MG / CAP
12/31/1987
NU-FOLIC
nu-pharm inc
02239233
Tablet - Oral
5 MG / TAB
N/A

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.